Author: Miles David
Publisher: Adis International
ISSN: 0012-6667
Source: Drugs, Vol.67, Iss.12, 2007-01, pp. : 1800-1801
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer
Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. :
Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
Drugs, Vol. 72, Iss. 3, 2012-02 ,pp. :